BR9804720A - Sistema de expressão controlado por vìrus ou oncogene. - Google Patents

Sistema de expressão controlado por vìrus ou oncogene.

Info

Publication number
BR9804720A
BR9804720A BR9804720-5A BR9804720A BR9804720A BR 9804720 A BR9804720 A BR 9804720A BR 9804720 A BR9804720 A BR 9804720A BR 9804720 A BR9804720 A BR 9804720A
Authority
BR
Brazil
Prior art keywords
nucleic acid
acid construct
gene
component
transcription factor
Prior art date
Application number
BR9804720-5A
Other languages
English (en)
Inventor
Rolf Dr Mueller
Hanns-Harald Dr Sedlacek
Original Assignee
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh
Publication of BR9804720A publication Critical patent/BR9804720A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Abstract

Patente de Invenção: <B>''SISTEMA DE EXPRESSãO CONTROLADO POR VìRUS OU ONCOGENE''<D>. A invenção refere-se a um construto de ácido nucléico para expressar um gene efetor, com o construto de ácido nucléico contendo um promotor I (componente a) que controla a expressão de um gene fator de transcrição (componente b) que está do mesmo modo contido no construto de ácido nucléico, e contendo um promotor II (componente c) ao qual o produto de gene do gene de fator de transcrição liga-se especificadamente e que controla a expressão de um gene efetor (componente d) que está do mesmo modo contido no construto de ácido nucléico, em que a atividade do produto de gene do gene de fator de transcrição depende de uma ou mais proteínas reguladoras celulares que ligam-se especificadamente a este produto de gene e efetuam sua atividade, a uma célula isolada que contém o dito construto de ácido nucléico, ao uso do dito construto para a preparação de uma droga para o tratamento de doenças, ao uso da dita célula para a mesma finalidade e a um processo para a preparação do construto de ácido nucléico.
BR9804720-5A 1997-11-21 1998-11-20 Sistema de expressão controlado por vìrus ou oncogene. BR9804720A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19751587A DE19751587A1 (de) 1997-11-21 1997-11-21 Onkogen- oder virusgesteuerte Expressionssysteme

Publications (1)

Publication Number Publication Date
BR9804720A true BR9804720A (pt) 2000-03-28

Family

ID=7849391

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9804720-5A BR9804720A (pt) 1997-11-21 1998-11-20 Sistema de expressão controlado por vìrus ou oncogene.

Country Status (12)

Country Link
US (1) US6465246B1 (pt)
EP (1) EP0922768A3 (pt)
JP (1) JP2000106886A (pt)
KR (1) KR19990045475A (pt)
CN (1) CN1221033A (pt)
AR (1) AR013772A1 (pt)
AU (1) AU745614B2 (pt)
BR (1) BR9804720A (pt)
CA (1) CA2251257A1 (pt)
CZ (1) CZ376898A3 (pt)
DE (1) DE19751587A1 (pt)
HU (1) HUP9802681A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19756975A1 (de) 1997-12-20 1999-06-24 Hoechst Marion Roussel De Gmbh Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
DE19947668A1 (de) 1999-10-04 2001-04-19 Univ Eberhard Karls Tumorspezifischer Vektor für die Gentherapie
JP2003511355A (ja) * 1999-10-06 2003-03-25 ビーエーエスエフ アクチェンゲゼルシャフト 併用療法のためのエンドセリンシグナル伝達経路のインヒビターおよびαｖβ３受容体アンタゴニスト
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
CA2408830A1 (en) * 2000-05-12 2001-11-22 The Regents Of The University Of California Treatment of human papillomavirus (hpv)-infected cells
WO2002068668A2 (en) * 2001-02-22 2002-09-06 Immunex Corporation Compositions and methods for production cell culture
JP4666335B2 (ja) * 2002-09-04 2011-04-06 晶夫 岸田 機械的振動による生物機能の制御方法とその装置
WO2005085455A1 (en) * 2004-03-09 2005-09-15 Kam Man Hui Compositions and methods for treating disease
EP1943265B1 (en) * 2005-10-01 2012-09-12 Charles Stout Regulatable fusion promoters
WO2007061759A1 (en) * 2005-11-18 2007-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Delayed expression vectors
WO2007061762A2 (en) * 2005-11-18 2007-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt And Human Services Non-viral gene delivery complex
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
US5674703A (en) * 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
CN1141059A (zh) 1993-11-22 1997-01-22 昂尼克斯药物公司 P53-结合多肽和编码该多肽的多核苷酸
US5700657A (en) 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
US5659024A (en) 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
WO1996006938A1 (de) 1994-08-26 1996-03-07 Hoechst Aktiengesellschaft Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
DK0807183T3 (da) 1994-08-26 2001-03-05 Aventis Pharma Gmbh Genterapi af sygdomme, der fremkaldes af immunsystemet, ved hjælp af et cellespecifikt aktivt stof, der reguleres af cellec
FR2736915B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Rorer Sa Variants de la proteine p53 et utilisations therapeutiques
GB9616685D0 (en) * 1995-10-02 1996-09-25 Cancer Res Campaign Tech Antitumour vector constructs and methods
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19756975A1 (de) * 1997-12-20 1999-06-24 Hoechst Marion Roussel De Gmbh Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung

Also Published As

Publication number Publication date
AU9325698A (en) 1999-06-10
KR19990045475A (ko) 1999-06-25
EP0922768A3 (de) 2000-01-05
EP0922768A2 (de) 1999-06-16
JP2000106886A (ja) 2000-04-18
US6465246B1 (en) 2002-10-15
AU745614B2 (en) 2002-03-28
CZ376898A3 (cs) 1999-06-16
CA2251257A1 (en) 1999-05-21
HU9802681D0 (en) 1999-02-01
AR013772A1 (es) 2001-01-10
HUP9802681A1 (hu) 2000-10-28
CN1221033A (zh) 1999-06-30
DE19751587A1 (de) 1999-07-29

Similar Documents

Publication Publication Date Title
BR9804720A (pt) Sistema de expressão controlado por vìrus ou oncogene.
Bukrinsky et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells
Gadaleta et al. Aging and mitochondria
Virshup et al. Mechanism of activation of simian virus 40 DNA replication by protein phosphatase 2A
Andreyev et al. Carboxyatractylate inhibits the uncoupling effect of free fatty acids
Barbacci et al. The Structural Basis for the Specificity of Epidermal Growth Factor and Heregulin Binding (∗)
Huang et al. Bovine brain-derived growth factor. Purification and characterization of its interaction with responsive cells.
Bruni et al. Nuclear Respiratory Factor 2 Induces the Expression of Many but Not All Human Proteins Acting in Mitochondrial DNA Transcription and Replication 2
Kataoka et al. Differentially expressed Maf family transcription factors, c-Maf and MafA, activate glucagon and insulin gene expression in pancreatic islet alpha-and beta-cells
Anderson et al. Identification of poly (ADP-ribose) polymerase as a transcriptional coactivator of the human T-cell leukemia virus type 1 Tax protein
Dechant et al. The neurotrophin receptor p75 binds neurotrophin-3 on sympathetic neurons with high affinity and specificity
BR9705527A (pt) Sistemas de expressão auto-melhorador, farmacologicamente controláveis.
Schubert et al. A chick neural retina adhesion and survival molecule is a retinol-binding protein.
Delmolino et al. COP‐1, a member of the CCN family, is a heparin‐induced growth arrest specific gene in vascular smooth muscle cells
Chu et al. Reciprocal regulation of gene transcription by insulin. Inhibition of the phosphoenolpyruvate carboxykinase gene and stimulation of gene 33 in a single cell type.
BR9607628A (pt) Mólecula proteinácea biologicamente isolada, molécula recombinante, fragmento de peptìdeo, molécula de ácido nucleico, composição farmacêutica, e, processos para preparar uma molécula recombinante e para induzir a proliferação astroglial em um mamìfero
Zhou et al. Keratinocyte growth factor stimulates CFTR-independent fluid secretion in the fetal lung in vitro
EP1611238A2 (en) Glutamate transport modulatory compounds and methods
Kelm et al. The single-stranded DNA-binding proteins, Purα, Purβ, and MSY1 specifically interact with an exon 3-derived mouse vascular smooth muscle α-actin messenger RNA sequence
Xu et al. Methyltransferase-like 3 rescues the amyloid-beta protein-induced reduction of activity-regulated cytoskeleton associated protein expression via YTHDF1-dependent N6-methyladenosine modification
BR9800913A (pt) Promotor de gene cdc25b, preparação e uso do mesmo.
Sun et al. Nuclear factor 1 is a component of the nuclear matrix
Falaschi et al. DNA-binding proteins and DNA-unwinding enzymes in eukaryotes
ATE263779T1 (de) Wässrige proteinzusammensetzung, enthaltende glykoproteine, verfahren zur herstellung und verwendungen
Rincón-Arano et al. YY1 and GATA-1 interaction modulate the chicken 3′-side α-globin enhancer activity

Legal Events

Date Code Title Description
TC Change of name
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7AE 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1886 DE 27/02/2007.